As some here have indicated, in the long run, utilization will be more important then placement. However, in the near term you need placements before you can have utilization. On the surface, the commercialization phase is progressing in an orderly and professional manner. In late October, there will be at least one national dermatology convention. Attending that event will be highly respected dermatologist who have been using Melafind. This will accelerate placements as word about the device continues to spread.
this post is dead on with one exception.....no insurance reimbursement is a killer...perhaps it will come in the future but many will have biopsies done because they are covered by insurance....mela is less painful experience but more painful to the pocket....
According to the CEO, the company is delaying submission for reimbursement until they have developed sufficient empirical evidence to justify the maximum reimbursement. In all liklihood they will submit their application in 2013. In the meantime, would you personally rather have your insurance company reimburse you for a biopsy on your face or pay the $150 bucks for utilization of the melafind device? Bottom line though, you are right, reimbursement will be a good thing to have.